OncoMatch/Clinical Trials/NCT07728942
SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors
Is NCT07728942 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including SLR-108 and SLX-1411 for metastatic solid tumors.
Treatment: SLR-108 · SLX-1411 — This is a Phase 1 study evaluating the feasibility of using SLR-108 for positron-emission tomography (PET) imaging of metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: commercially available therapies with demonstrated survival benefit for the subject's cancer — subject's cancer
Prior receipt of commercially available therapies that are indicated for the subject's cancer and have a demonstrated survival benefit for that indication
Lab requirements
Blood counts
adequate hematological profile
Kidney function
adequate renal function
Liver function
adequate hepatic profile
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hoag Memorial Hospital Presbyterian · Newport Beach, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07728942 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received commercially available therapies with demonstrated survival benefit for the subject's cancer.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify